Table 3

Main effects of tested SNPs on BD risk

Nearest gene(s)	SNP	Stage	Genotype/allele	Case	freq	Control	freq	P values	P_c values	OR (95% CI)	Statistical power
CEBPB- PTPN1	rs913678	Stage1	CC	251	0.526	280	0.423	5.69E−04	3.75E−02	1.515 (1.196 to 1.920)	0.998
CT	186	0.390	303	0.458	2.26E−02	NS	0.757 (0.596 to 0.962)
TT	40	0.084	79	0.119	0.054	–	0.675 (0.453 to 1.008)
C	688	0.721	863	0.652	4.59E−04	1.01E−02	1.382 (1.153 to 1.656)
Stage2	CC	405	0.534	379	0.476	2.35E−02	NS	1.259 (1.031 to 1.536)
CT	297	0.391	337	0.423	0.198	–	0.876 (0.715 to 1.072)
TT	57	0.075	80	0.101	0.077	–	0.727 (0.509 to 1.037)
C	1107	0.729	1095	0.688	1.11E−02	4.43E−02	1.222 (1.047 to 1.428)
Combined	CC	656	0.531	659	0.452	4.60E−05	3.04E−03	1.371 (1.178 to 1.596)
CT	483	0.391	640	0.439	1.15E−02	NS	0.820 (0.703 to 0.956)
TT	97	0.078	159	0.109	7.01E−03	NS	0.696 (0.534 to 0.907)
C	1795	0.726	1958	0.671	1.37E−05	3.01E−04	1.297 (1.154 to 1.459)
LACC1	rs9316059	Stage1	TT	17	0.036	56	0.085	7.87E−04	5.19E−02	0.397 (0.228 to 0.692)	0.970
TA	170	0.357	292	0.445	2.95E−03	NS	0.693 (0.543 to 0.883)
AA	289	0.607	308	0.470	4.68E−06	3.09E−04	1.746 (1.374 to 2.219)
T	204	0.214	404	0.308	6.96E−07	1.53E−05	0.613 (0.505 to 0.744)
Stage2	TT	46	0.061	62	0.078	0.176	–	0.762 (0.513 to 1.131)
TA	260	0.342	334	0.420	1.55E−03	1.86E−02	0.718 (0.584 to 0.882)
AA	454	0.597	399	0.502	1.56E−04	1.87E−03	1.473 (1.205 to 1.808)
T	352	0.232	458	0.288	3.35E−04	1.34E−03	0.745 (0.634 to 0.875)
Combined	TT	63	0.051	118	0.081	1.76E−03	NS	0.607 (0.442 to 0.832)
TA	430	0.348	626	0.431	9.95E−06	6.56E−04	0.703 (0.601 to 0.822)
AA	743	0.601	707	0.487	3.57E−09	2.36E−07	1.586 (1.360 to 1.849)
T	556	0.225	862	0.297	2.25E−09	4.95E−08	0.687 (0.607 to 0.777)
RIPK2	rs10094579	Stage1	AA	29	0.061	30	0.045	0.246	–	1.336 (0.806 to 2.302)	0.996
CA	205	0.431	228	0.345	3.52E−03	NS	1.433 (1.125 to 1.826)
CC	242	0.508	402	0.609	7.27E−04	4.80E−02	0.664 (0.523 to 0.842)
A	263	0.276	288	0.218	1.44E−03	3.16E−02	1.368 (1.128 to 1.659)
Stage2	AA	58	0.077	47	0.059	0.157	–	1.332 (0.895 to 1.984)
CA	294	0.393	273	0.344	4.95E−02	NS	1.231 (1.000 to 1.514)
CC	397	0.530	473	0.596	8.56E−03	NS	0.763 (0.624 to 0.934)
A	410	0.274	367	0.231	6.84E−03	2.74E−02	1.252 (1.064 to 1.473)
Combined	AA	87	0.071	77	0.053	0.053	–	1.366 (0.995 to 1.875)
CA	499	0.407	501	0.345	8.58E−04	NS	1.306 (1.116 to 0.528)
CC	639	0.522	875	0.602	2.79E−05	1.84E−03	0.720 (0.618 to 0.840)
A	673	0.275	655	0.225	3.15E−05	6.93E−04	1.302 (1.149 to 1474)
ADO- EGR2	rs224127	Stage1	GG	67	0.140	121	0.185	4.40E−02	NS	0.717 (0.518 to 0.992)	0.985
GA	217	0.454	324	0.496	0.161	–	0.844 (0.666 to 1.070)
AA	194	0.406	208	0.319	2.44E−03	NS	1.461 (1.143 to 1.869)
A	605	0.636	740	0.567	1.53E−03	3.36E−02	1.318 (1.111 to 1.564)
Stage2	GG	90	0.118	135	0.170	3.73E−03	4.48E−02	0.655 (0.491 to 0.873)
GA	366	0.482	378	0.477	0.847	–	1.020 (0.836 to 1.245)
AA	304	0.400	280	0.353	5.64E−02	–	1.221 (0.994 to 1.500)
A	974	0.641	938	0.591	4.70E−03	1.88E−02	1.232 (1.066 to 1.425)
Combined	GG	157	0.127	256	0.177	3.25E−04	2.14E−02	0.675 (0.544 to 0.837)
GA	583	0.471	702	0.485	0.452	–	0.943 (0.810 to 1.098)
AA	498	0.402	488	0.337	5.20E−04	3.43E−02	1.321 (1.129 to 1.546)
A	1579	0.638	1678	0.580	1.71E−05	3.77E−04	1.274 (1.141 to 1.422)

Statistical power was estimated from effect size in the original Turkish data sets, allele frequency and sample size in the Chinese Han population.
BD, Behcet’s disease; p_c value, the Bonferroni corrected p value; NS, not significant; SNP, single nucleotide polymorphism.